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Abstract
Background: Dysregulated transforming growth factor β (TGFβ) signaling is implicated in osteoarthritis
development, making normalizing TGFβ signaling a possible therapy. Theoretically, this can be achieved with small
molecule inhibitors specifically targeting the various TGFβ receptors and downstream mediators. In this study we
explore in primary chondrocytes the use of small molecule inhibitors to target TGFβ-induced pSmad1/5/9-,
pSmad2/3- and TGFβ-activated kinase 1 (TAK1)-dependent signaling.
Method: Primary bovine chondrocytes and explants were isolated from metacarpophalangeal joints. To modulate
TGFβ signaling the activin receptor-like kinase (ALK)1/2/3/6 inhibitor LDN-193189, the ALK4/5/7 inhibitor SB-505124
and the TAK1 inhibitor (5Z)-7-Oxozeaenol were used. pSmad1/5 and pSmad2 were measured using western blot
analysis and TGFβ1-induced gene expression was measured using quantitative real time PCR (qPCR).
Results: In chondrocytes, TGFβ1 strongly induced both pSmad1/5 and pSmad2. Remarkably, LDN-193189 did not
inhibit TGFβ-induced pSmad1/5. In contrast, SB-505124 did inhibit both TGFβ-induced Smad2 and Smad1/5
phosphorylation. Furthermore, (5Z)-7-Oxozeaenol also profoundly inhibited TGFβ-induced pSmad2 and pSmad1/5.
Importantly, both SB-505124 and (5Z)-7-Oxozeaenol did not significantly inhibit constitutively active ALK1, making
an off-target effect unlikely. Additionally, LDN-193189 was able to potently inhibit BMP2/7/9-induced pSmad1/5,
showing its functionality. On gene expression, LDN-193189 did not affect TGFβ1-induced regulation, whereas both
SB-505124 and (5Z)-7-Oxozeaenol did. Similar results were obtained in cartilage explants, although pSmad1/5 was
not strongly induced by addition of TGFβ1.
Conclusion: Our data suggest that ALK5 kinase activity plays a central role in both TGFβ-induced Smad1/5 and
Smad2/3 phosphorylation, making it difficult to separate both pathways with the use of currently available small
molecule inhibitors. Furthermore, our data regarding (5Z)-7-Oxozeaenol suggest that TAK1 facilitates Smad-
dependent signaling.
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Background
Transforming growth factor β (TGFβ) plays a crucial
role in regulation of tissue homeostasis via its control
over diverse cellular processes such as proliferation, dif-
ferentiation and matrix formation. By binding to differ-
ent receptors of the activin-receptor like kinase (ALK)
family, TGFβ induces intracellular carboxy-terminal (C-
terminal) phosphorylation of receptor-regulated Smad
(R-Smad) proteins. Phosphorylated R-Smads form com-
plexes with the common-mediator Smad; Smad4, and
these complexes translocate to the nucleus where they
bind DNA to regulate gene transcription via recruitment
of transcription factors [1, 2]. Use of different ALKs can
result in activation of different R-Smads; activation of
ALK5 (TGFβR1) induces phosphorylation of Smad2 and
Smad3, whereas activation of an ALK1 (or 2 or 3) com-
plex mediates phosphorylation of Smad1, Smad5 and
Smad9 [3, 4]. However, TGFβ signaling is not limited to
R-Smads as Smad-independent signaling can occur by
activation of e.g. TGFβ-activated kinase 1 (TAK1 or
MAP3K7). Smad-independent signaling results in activa-
tion of various downstream signaling pathways, includ-
ing the JUN N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) pathways [5].
In many tissues, e.g. in cartilage, phosphorylated
Smad2/3 and Smad1/5 have opposing functions [6, 7].
In cartilage, phosphorylated Smad3 guards chondrocyte
phenotype against deleterious hypertrophy and produc-
tion of catabolic enzymes like matrix metalloproteinases
(MMPs) [8–10]. In contrast, phosphorylated Smad1/5 is
essential for chondrocyte hypertrophy [11, 12], and is as-
sociated with expression of matrix metalloproteinase 13
(MMP13), the main cartilage-degrading enzyme [13].
Therefore, balancing TGFβ signaling via Smad2/3 or
Smad1/5 is important for chondrocytes to maintain cel-
lular homeostasis and deregulation of this balance has
been proposed as a cause of disease, e.g. osteoarthritis
(OA) [4, 13]. It would be of great benefit if cellular re-
sponses to TGFβ could be directed towards either the
Smad1/5 or Smad2/3 pathway; this would enable block-
ade of deleterious pathways while maintaining beneficial
signaling.
Inhibiting Smad phosphorylation can be achieved by
blocking the kinase domain of ALK receptors. Small
molecules have been developed that specifically inhibit
the kinase activity of ALK4, ALK5 and ALK7, the recep-
tors that phosphorylate Smad2 and Smad3, or ALK1,
ALK2, ALK3 and ALK6, the receptors that phosphoryl-
ate Smad1, Smad5 and Smad9 [14, 15]. In this study we
investigated in chondrocytes and cartilage explants the
use of SB-505124 [15, 16], an inhibitor of ALK4/5/7
kinase activity and LDN-193189, an inhibitor of the
ALK1/2/3/6 kinase activity [14, 16] to study their ability
to direct R-Smad signaling and downstream effects.
Furthermore, we used (5Z)-7-Oxozeaenol as a selective
inhibitor of TAK1 kinase activity to evaluate the import-
ance of TAK1 in TGFβ signaling in chondrocytes [17,
18], because of the ability of TAK1 to induce the JNK
and p38 MAPK pathways and MMP production in
cartilage [19, 20].
In this study we show that inhibition of ALK4/5/7 kin-
ase activity prevented TGFβ1-induced C-terminal phos-
phorylation of both Smad2 and Smad1/5. Furthermore,
treatment with (5Z)-7-Oxozeaenol, a selective TAK1
kinase inhibitor, attenuated phosphorylation of both
Smad2/3 and Smad1/5 and expression of Smad target
genes. Use of the ALK1/2/3 inhibitor LDN-193189 did
not affect TGFβ1-induced R-Smad phosphorylation or
gene expression. In conclusion, our data show that in
cartilage the activity of the ALK5 kinase domain is es-
sential for TGFβ1 signaling, whereas ALK1 kinase activ-
ity is not. Furthermore, our results obtained with (5Z)-7-
Oxozeaenol underline that TAK1 kinase activity is facili-
tating R-Smad phosphorylation. Our study indicates that
TGFβ1-induced Smad1/5 and Smad2/3 phosphorylation
cannot be selectively targeted by using the small
molecule inhibitors SB-505124 and LDN-193189.
Methods
Chondrocyte culture
Primary bovine chondrocytes were isolated from the
metacarpophalangeal joint of cows (2–5 years old) ob-
tained from a slaughterhouse within 3 hours post mortem.
Chondrocytes were obtained by incubating cartilage slices
overnight in Collagenase B (for details see [21]). Chondro-
cytes were seeded in DMEM/F12 1:1 containing 10% fetal
calf serum (Thermo Scientific UK) at a density of 0.5 × 105
cells per cm2 in 6-well plates (Greiner Bio-one Inter-
national, the Netherlands) for protein studies, or in 24-
well plates (Bio-one International, the Netherlands) for
mRNA experiments. Cells were cultured for 1 week at
37 °C and 5% CO2 before the start of the experiments. For
explant studies, four 7-mm2 explants per condition were
pooled in 1 ml of medium. Both monolayer and explant
studies were repeated in different donors.
Adenoviral transfection of primary chondrocytes
Adenoviruses were used to induce expression of consti-
tutively active (ca)ALK1 [4], constitutively active ALK5
[4] and the CAGA12-luciferace reporter construct [22] in
primary chondrocytes. Cells were rinsed twice with
saline, and adenoviruses were added in a multiplicity of
infection of 200 for 3 h at 37 °C in a minimal volume of
DMEM/F12 1:1. Hereafter, cells were washed twice with
saline, and DMEM/F12 1:1 was added. Cells were used
48 h after transfection.
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Inhibition of TGFβ1 signaling
Before stimulation, cells were deprived of serum for 24 h
and thereafter stimulated with 1 ng/ml recombinant human
TGFβ1 (Biolegend, the Netherlands) for 2 or 24 h. In experi-
ments where inhibitors were used, DMSO was used as ve-
hicle control. To block TAK1 activity, we used (5Z)-7-
Oxozeaenol [17] (Tocris Bioscience) in a concentration of
0.5 μM. To inhibit ALK5 kinase, we used SB-505124 [15]
(Sigma Aldrich) in a concentration of 5 μM. For inhibition
of ALK1 kinase, LDN-193189 [14] (Axon Medchem) was
used in a concentration of 0.05 μM. This concentration of
LDN-193189 is well above its reported half maximal inhibi-
tory concentration (IC50), 0.8 nM for ALK1, but far below
its IC50 for ALK5 of 350 nM [16, 23]. Cells were pre-
incubated with the inhibitors for 1 h prior to addition of
TGF-β1. Either 2 or 24 h after addition TGF-β1, medium
was removed and TRI-reagent was added for RNA isolation.
Protein isolation
To isolate proteins from monolayer cultures, cells were
lysed on ice using lysis buffer (Cell signaling, USA) con-
taining a protease inhibitor cocktail (complete, Roche
Diagnostics, Germany) and subsequently sonicated on
ice using a Bioruptor (Diagenode, USA). With a BCA-
assay (Thermo Scientific, USA) protein concentration
was measured and after addition of Laemmli sample
buffer, samples were boiled for 5 minutes at 99 °C.
To isolate proteins from explants, four 7-mm2 ex-
plants were homogenized using a Mikro-dismembrator
(B. Braun, Germany) and dissolved in 1 ml ice cold
radioimmunoprecipitation assay (RIPA) buffer with
added 1 mM Na3VO4 and protease inhibitor cocktail
(Roche Diagnostics, Germany). After 1 h incubation on
a roller bench at 4 °C, samples were spun down for 3 mi-
nutes at 104 × g and the pellet was discarded. Cetylpyri-
dinium chloride was added up to a concentration of 1%
(m/v) and samples were incubated on a roller bench for
1 h at 4 °C. Hereafter, samples were spun down twice for
15 minutes at 104 × g at 4 °C and the pellet was dis-
carded. Using 10 kDa centrifugal filter units (Millipore,
USA) the supernatant was concentrated to a volume of
50 μl. Subsequently, proteins were precipitated by
addition of 950 μl of 20% m/v trichloroacetic acid and
0.1% m/v dithiothreitol in aceton at -20 °C and spinning
samples down for 15 minutes at 6700 × g at 4 °C. Next,
the pellets were washed three times with 0.1% m/v di-
thiothreitol in aceton at -20 °C. Finally, the pellets were
dried under vacuum for 20 minutes and dissolved in
100 μl 1% m/v sodium dodecyl sulfate in 100 mM
tris(hydroxymethyl)aminomethane in H2O pH 9.0.
Detection of proteins using SDS-PAGE and western blot
Proteins were seperated on a 7.5% Bisacrylamide gel,
and transferred to a nitrocellulose membrane using wet
transfer (Towbin buffer, 2.5 h 275 mA at 4 °C). After
overnight incubation at 4 °C with 1:1000 polyclonal
Rabbit anti P-Smad1/5 (S463/465)/Smad8 (S426/428)
(Cell signaling, USA) or anti P-Smad2 (S465/467) (Cell
signaling, USA), membranes were incubated with 1:1500
polyclonal Goat anti Rabbit labeled with horseradish
peroxidase (HRP) (DAKO, Belgium) for 1 h. Hereafter,
enhanced chemiluminescence using ECL plus (GE
Healthcare, UK) was used to visualize the proteins. To
visualize overexpression of constitutively active ALKs, a
rabbit polyclonal antibody directed against their internal
HA tag was used: HA-probe Antibody (Y-11) (Santa
Cruz, USA) (1:1000). As loading control either Gapdh
was stained with an anti-Gapdh mouse mAb (1G5)
(Sigma Aldrich, Germany) (1:10 000) in combination
with IRDye 680RD Donkey anti mouse (1:10 000) (Licor,
USA) using the Odyssey detection system (Licor, USA)
or Vinculin with a rabbit pAb (H300) (Santa Cruz, USA)
(1:1000) in combination with HRP-labeled Goat-anti
Rabbit (1:2000) (DAKO, Denmark) using ECL. Finally,
blots were quantified using ImageJ.
Detection of gene expression
TRI-reagent (Sigma-Aldrich, Germany) was used for
RNA isolation according to the manufacturer’s protocol
(for details see [21]). RNA concentration was measured
using a Nanodrop photospectrometer (Thermo Scien-
tific, USA). Per sample, 1 μg of RNA was treated with
DNAse (Life Technologies, USA), which was subse-
quently inactivated at 65 ° C with 1 μl 25 mM EDTA
(Life Technologies, USA). To perform reverse transcript-
ase reaction, 1.9 μl ultra pure water, 2.4 μl 10 × DNAse
buffer, 2.0 μl 0.1 M DTT, 0.8 μl 25 mM dNTP, 0.4 μg
oligo dT primer, 1 μl 200 U/μl M-MLV Reverse tran-
scriptase (all Life Technologies, USA) and 0.5 μl 40 U/μl
RNAsin (Promega, the Netherlands) was added, and
samples were incubated for 5 minutes at 25 °C, 60 mi-
nutes at 39 °C, and 5 minutes at 95 °C using a thermo
cycler. The obtained cDNA was diluted 10 times in ultra
pure water, and gene expression was measured using
1 μM of validated cDNA-specific primers (Biolegio, the
Netherlands; see Table 1) in a quantitative real-time
polymerase chain reaction (qPCR) using SYBR green
master mix (Applied Biosystems). The following proto-
col was used: after 10 minutes at 95 °C, 40 cycles of
15 sec at 95 °C and 1 minute at 60 °C each were run.
Hereafter a melting curve was made to verify gene-
specific amplification. For calculations of the -ΔCt, two
reference genes were used: glyceraldehyde 3-phosphate
dehydrogenase and ribosomal protein S14.
Statistics
All quantitative data are expressed as a mean of multiple
repeats ± SD. For every analysis data were checked for
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normality using the Shapiro-Wilk test. One-way analysis
of variance (ANOVA) with Tukey multiple comparison
post-hoc test was used to determine the significance. The
statistical analyses were performed using Graphpad Prism
5.0 software.
Results
SB-505124 and (5Z)-7-Oxozeaenol both inhibit TGFβ1-
induced Smad1/5 and Smad2/3 phosphorylation whereas
LDN-193189 does not
To begin, we confirmed in primary bovine chondrocytes
the expression of the receptors that TGFβ can use to in-
duce Smad2/3 phosphorylation i.e. ALK5 or Smad1/5
phosphorylation, i.e. ALK1, ALK2 and ALK3 [3, 4]. All
four receptors were readily detected using qPCR
(Additional file 1: Figure S1), and indeed confirmed that
stimulation of chondrocytes with TGFβ1 results in both
Smad2 and Smad1/5 phosphorylation (Fig. 1a).
Subsequently, we analyzed the effects of the ALK4/
5/7-kinase inhibitor SB-505124, the ALK1/2/3-kinase
inhibitor LDN-193189 and the TAK1-kinase inhibitor
(5Z)-7-Oxozeaenol on TGFβ1-induced R-Smad phos-
phorylation (Fig. 1a, b and c). Strikingly, addition of
5 μM SB-505124 not only inhibited Smad2 phosphor-
ylation, but also pSmad1/5 phosphorylation. Remark-
ably, treatment with 0.5 μM (5Z)-7-Oxozeaenol also
resulted in inhibition of TGFβ1-induced Smad1/5 and
Smad2 phosphorylation. Noteworthy, addition of
0.05 μM LDN-193189 did not affect TGFβ1-induced
Smad1/5 phosphorylation but did significantly en-
hance TGFβ-induced pSmad2.
To investigate if the striking effect of SB-505124 on
Smad1/5 phosphorylation was a dose-dependent effect,
we performed a dose-response experiment (Fig. 1d and e).
This experiment showed that at all tested doses (0.1, 0.5,
1, 5, 10 and 25 μM), SB-505124 inhibited TGFβ1-induced
Smad1/5 phosphorylation, and that Smad1/5 phosphoryl-
ation was inhibited more potently than that of Smad2.
Therefore, to address if ALK1 inhibition was a possible
off-target effect of SB-505124, this compound was added
to cells over-expressing constitutively active (ca)ALK1 or
caALK5. This experiment showed that SB-505124 did not
affect caALK1-induced Smad1/5 phosphorylation (Fig. 2a
and b), but did inhibit caALK5-induced Smad2 phosphoryl-
ation (Fig. 2a and b). Therefore, SB-505124 is specific for
ALK5 kinase and does not inhibit ALK1 kinase. The same
experimental setup was used to address the specificity of
(5Z)-7-Oxozeaenol, and no significant inhibitory effect of
this compound on either caALK1 or caALK5 function was
detected, making it unlikely that either the ALK1 or ALK5
kinase domain is an off-target of (5Z)-7-Oxozeaenol.
To investigate if the lack of effect of LDN-193189 on
TGFβ1-induced Smad1/5 was maybe dose-dependent, we
added a 10 times higher dose of LDN-193189 (0.5 μM) to
the cells, but were still unable to inhibit TGFβ1-induced
Smad1/5 phosphorylation (Fig. 2c). Therefore we sought to
validate the function of LDN-193189. To do this, we added
0.05 μM LDN-193189 to chondrocytes over-expressing
caALK1 and observed that this blocked caALK1-induced
Smad1/5 phosphorylation (Fig. 2a and b), Furthermore, the
effect of 0.05 μM LDN-193189 on bone morphogenic pro-
tein (BMP) signaling was also investigated (Fig. 2d) by
stimulating primary chondrocytes for 1 h with either
Table 1 Sequence and efficiency of the primers used in this study
Gene NCBI reference sequence P (bp) E (%) Forward primer Reverse primer
bGapdh NM_001034034.2 90 101 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bRps14 NM_001077830.2 125 105 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bAlk1 NM_001083479.1 109 100 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAlk2 NM_176663.3 61 105 CGTTGGAGACAGCACTTTAGCA AGAGCCGCTTCCCGATGTA
bAlk3 NM_001076800.1 142 96 GAGCAAGATGAAGCATTTATTCCA CAACCTGCCGAACCATCTG
bAlk5 NM_174621.2 75 94 CAGGACCACTGCAATAAAATAGAACTT TGCCAGTTCAACAGGACCAA
bSerpine1 NM_174137.2 55 99 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bId1 NM_001097568.2 73 107 GCTCCGCTCAGCACTCTCAA GATCGTCCGCTGGAACACA
bMmp3 NM_001206637.1 130 106 GAATCTGTGCCTCCCGAACC TCCTGAAAGATTTCCGCCAA
bSmad7 NM_001192865.1 72 98 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1 NM_001166068.1 80 107 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bJunb NM_001075656.1 139 97 CCTTCTACCACGACGACTCA CCGGGTGCTTTGAGATTTCG
bNgf NM_001099362.1 110 85 CAGCTCTTTTGATCGGCATACA TGTGTCAAGGGAATGCTGAAGT
bFn1 NM_001163778.1 95 96 GCACCACTCCCGACATTACT CTGATCGGCATGGACCACTT
bCol2a1 NM_001001135.2 60 97 TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
P is product length in base pairs, E is efficiency in percentage. Alk1 is also known as Acvrl1, Alk2 as Acvr1, Alk3 as Bmpr1a and Alk5 as Tgfbr1
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Fig. 1 SB-505124 and (5Z)-7-Oxozeaenol inhibit both transforming growth factor β1 (TGFβ1)-induced Smad1/5 and Smad2/3 phosphorylation
whereas LDN-193189 does not. a Primary bovine chondrocytes were pre-incubated with either 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol or
0.05 μM LDN-193189 for 1 h, and subsequently stimulated with 1 ng/ml TGFβ1 for 1 h, after which phosphorylated Smads were visualized using
western blot by specific antibodies. kDa, kilodalton. b Quantification of the pSmad1/5 signal (as shown in a) in four experiments. pSmad1/5 levels
were normalized to vinculin levels and plotted as a relative amount in arbitrary units (AU) compared to the control group: #p≤ 0.001 compared
to unstimulated; ***p≤ 0.001. c Quantification of the pSmad2 signal (as shown in a) in four experiments. pSmad2 levels were normalized to vinculin
levels and plotted as a relative amount in AU compared to the control group: #p≤ 0.001 compared to unstimulated; ***p≤ 0.001. d Dose-response
effect of SB-505124 on TGFβ1 signaling in primary chondrocytes. e Quantification of pSmad levels (shown in d); levels were normalized to vinculin
levels and plotted as a relative amount in percentage compared to the control group
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the ALK2/3 ligands BMP2 or BMP7 [24] or the
ALK1/2 ligand BMP9 [25, 26]. We observed that
BMP-induced Smad1/5 phosphorylation was clearly
inhibited by 0.05 μM LDN-193189. Together, these
experiments strongly confirm the function of 0.05 μM
LDN-193189 in primary chondrocytes.
In conclusion, in primary chondrocytes, TGFβ1-induced
Smad1/5 phosphorylation is unaffected by LDN-193189,
whereas both Smad2/3 and Smad1/5 phosphorylation are
inhibited by SB-505124 and (5Z)-7-Oxozeaenol.
SB-505124 fully and (5Z)-7-Oxozeaenol partly inhibit
TGFβ1-induced Smad-dependent gene expression
whereas LDN-193189 does not
Next, we analyzed the effects of TGFβ1 signaling inhibi-




Fig. 2 SB-505124 and (5Z)-7-Oxozeaenol do not affect constitutively active activin receptor-like kinase 1 (ALK1) whereas LDN-193189 does. a Primary bovine
chondrocytes were transfected with either constitutively active ALK1 (caALK1) or caALK5 and 2 days later treated with inhibitors for 1 h. A virus overexpressing
LacZ was used as control. Efficiency of overexpression was visualized on western blot by staining for the HA-tag attached to the caALKs. kDa kilodalton. b
Quantification of the pSmad1/5 and pSmad2 signal (as shown in a) in three experiments; #p≤ 0.001 compared to unstimulated. pSmad levels were
normalized to vinculin levels and plotted as a relative amount in arbitrary units (AU) compared to the control group; §p≤ 0.01 compared to unstimulated;
**p≤ 0.01; ***p≤ 0.001. c Dose-response effect of LDN-193189 on transforming growth factor β1 (TGFβ1) signaling in primary chondrocytes. pSmad levels
were normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) levels and indicated as a relative amount in AU compared to the control group.
d Primary chondrocytes were incubated for 1 h with LDN-193189 and subsequently stimulated for 1 h with 1 ng/ml (78 pM) TGFβ1, 25 ng/ml (1.94 nM)
recombinant human bone morphogenic protein 2 (rhBMP2), 25 ng/ml (3.06 nM) bone morphogenic protein 7 (BMP7) or 1 ng/ml (83 pM) bone morphogenic
protein 9 (BMP9). pSmad levels were normalized to Gapdh levels and indicated as a relative amount in AU compared to the control group
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For this, bId1 and bSerpine1 were used as markers of
pSmad1/5 and Smad3 signaling, respectively [4, 27] [22,
28]. Expression of bId1 was profoundly upregulated by
stimulation with 1 ng/ml of TGFβ1 (Fig. 3a). In accord-
ance with our western blot data on pSmad1/5, expression
of bId1 was inhibited by both SB-505124 and (5Z)-7-Oxo-
zeaenol, and was unaffected by LDN-193189. Expression
of bSerpine1 was upregulated by 1 ng/ml of TGFβ1 and
fully inhibited by SB-505124, but was only partly inibited
by (5Z)-7-Oxozeaenol (Fig. 3b). To confirm these effects
on pSmad3-dependent gene expression, we used the
CAGA12-luc construct, which produces luciferase specific-
ally in response to pSmad3. After 8 h, TGFβ-induced
CAGA12-luc activity was significantly inhibited by (5Z)-7-
Oxozeaenol and SB-505124, showing that pSmad3-
signaling is indeed lowered in these conditions. When the
effect of the inhibitors on multiple TGFβ1-induced
(Fig. 3c), genes like bSmad7, bMmp3, bCol2a1, bNgf,
bAlk5, bJunb, bFN1 and bTgfb1 was measured, none of
these genes was significantly downregulated by LDN-
193189, unlike SB-505124, which profoundly downregu-
lated bSmad, bNgf, bAlk5, bJunb, bFN1 and bTgfb1, or un-
like treatment with (5Z)-7-Oxozeaenol, which significantly
lowered bNgf, bTgfb1 and bMmp3 expression (Fig. 3d). Be-
cause a role for pSmad1/5 in the regulation of e.g. Smad7,
Junb and Col2a1 has been established [29–31], these data
indicate that the ALK5 kinase inhibitor SB-505124 inhibits
gene expression downstream of both pSmad2/3 and
pSmad1/5, whereas (5Z)-7-Oxozeaenol does so to a lesser
extent and in a more limited amount of genes. No effect
of LDN-193189 was observed on TGFβ1-induced gene
expression.
In intact cartilage, SB-505124 and-Oxozeaenol inhibit
TGFβ1-induced pSmad1/5 and pSmad2
As TGFβ1 signaling is known to be affected by cellular
context, we sought to validate our observations in
monolayer chondrocytes in intact cartilage ex vivo.
Therefore we stimulated cartilage explants with 1 ng/ml
TGFβ1 with or without inhibitors, and investigated
Smad phosphorylation. Explants were stimulated for 2 h
to allow for diffusion of TGFβ1 through the cartilage
matrix. In explants, 1 ng/ml TGFβ1 induced pSmad2,
but Smad1/5 phosphorylation was more difficult to de-
tect (Fig. 4a), in contrast to in monolayer cultures.
Therefore BMP9 was used as positive control, which, in
comparison to TGFβ, resulted in far stronger induction
of pSmad1/5 (for quantification see Additional file 2:
Figure S3). A smaller amount of pSmad1/5 was detected
in explants treated with TGFβ1 and SB-505124, (5Z)-7-
Oxozeaenol or LDN-193189 compared to TGFβ1-
treated samples alone. TGFβ-induced phosphorylation
of Smad2 was clearly inhibited by SB-505124 and partly
by (5Z)-7-Oxozeaenol (Fig. 4a), but on gene expression
bSerpine1 was only significantly inhibited by SB-505124
and not by (5Z)-7-Oxozeaenol (Fig. 4b). In explants, ex-
pression of bId1 could not be used as a read-out for
pSmad1/5 signaling, because TGFβ1 downregulated its
expression, in contrast to its induction in monolayer ex-
periments. This is a well-known Smad3-dependent cyto-
static effect of TGFβ1 [32], and further indicates that
TGFβ1 signaling differs between chondrocytes in mono-
layer and chondrocytes in intact cartilage. Notably,
LDN-193189 did downregulate bId1 expression, even in
absence of TGFβ1 (Additional file 3: Figure S2), demon-
strating the bioactivity of this compound in cartilage ex-
plants. Again, when multiple, TGFβ1-induced, Smad-
dependent, genes were measured (Fig. 4c) SB-505124
inhibited TGFβ1-induced expression of bSmad7, bNgf,
bFn1 and bTgfb1, and (5Z)-7-Oxozeaenol inhibited
TGFβ1-induced expression of bFn1, bTgfb1, whereas no
effect of LDN-193189 was observed. Therefore, SB-
505124 also inhibits both TGFβ1-induced Smad1/5 and
Smad2 phosphorylation and gene expression in intact
cartilage, whereas LDN-193189 does not. Furthermore,
(5Z)-7-Oxozeaenol partly inhibited both TGFβ1-induced
Smad1/5 and Smad2 phosphorylation.
Discussion
TGFβ1 signaling is a crucial regulator of chondrocyte
homeostasis. We investigated the impact of small mol-
ecule inhibitors on TGFβ1 signaling in primary chondro-
cytes both in vitro and ex vivo. We report that inhibition
of ALK4/5/7 kinase with SB-505124 lowered both
TGFβ1-induced Smad1/5 and Smad2/3 phosphorylation
and downstream gene expression, whereas inhibition of
ALK1/2/3/6 kinase with LDN-193189 did not affect
TGFβ1-induced Smad1/5 phosphorylation or transcrip-
tional activity. In addition, we showed that treatment
with (5Z)-7-Oxozeaenol, a selective TAK1 kinase inhibi-
tor, attenuated TGFβ1-induced R-Smad phosphorylation
and downstream gene expression.
In many tissues, including cartilage, TGFβ1 induces
pSmad1/5 and pSmad2/3 [3, 4, 7]. ALK5 is essential for
TGFβ1-induced Smad2/3 phosphorylation, whereas a
role for ALK1 [4], ALK2 and ALK3 [3] has been demon-
strated in TGFβ-induced Smad1/5 phosphorylation (see
Fig. 5). Remarkably, we found that specific inhibition of
ALK4/5/7 kinase with SB-505124 was sufficient to in-
hibit both TGFβ1-induced Smad2/3 and Smad1/5 phos-
phorylation and transcriptional activity. In contrast, we
were unable to block TGFβ1-induced Smad1/5 phos-
phorylation with LDN-193189, even though we used a
dose (0.05 μM) well above the reported IC50 of this in-
hibitor for ALK1 (0.8 nM), ALK2 (0.8 nM) and ALK3
(5.3 nM) [23]. Additionally, even a 10 times higher dose
of LDN-193189 (0.5 μM) was unable to block TGFβ1-
induced Smad1/5 phosphorylation. LDN-193189 has




Fig. 3 (See legend on next page.)
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been established as an efficient inhibitor of BMP type I
receptors, i.e. ALK1/2/3 and ALK6, both in vitro and in
vivo [14, 23, 33]. We were able to confirm this inhibitory
effect of LDN-193189 on BMP-induced Smad1/5 phos-
phorylation in primary chondrocytes by using BMPs that
signal via ALK1, ALK2 and/or ALK3, i.e. BMP2, BMP7
and BMP9 [24, 25]. Furthermore, we were also able to
block caALK1 activity with LDN-193189 in our primary
cell cultures. Together, these experiments indicate that
LDN-193189 is functional in primary bovine chondro-
cytes and blocks the ALK1, ALK2 and ALK3 kinase ac-
tivity at a dose of 0.05 μM. Therefore, our data indicate
that ALK1, ALK2 or ALK3 kinase activity is not required
for TGFβ1-induced Smad1/5 in primary chondrocytes
and cartilage. Notably, various studies using the LDN-
193189 precursor dorsomorphin also show that this
BMP type I receptor blocker is unable to block TGFβ1-
induced Smad1/5 phosphorylation, supporting our ob-
servations [34, 35].
Based on structural analyses of R-Smad-ALK interac-
tions, the ability to phosphorylate Smad1/5 is thought to
be limited to BMP type I receptors [36, 37]. Our data in-
dicate that ALK5 kinase activity is crucial, and possibly
sufficient, for TGFβ1-induced Smad1/5 phosphorylation.
In line with our data, it has previously been demon-
strated that inhibition of ALK5-kinase with SB-431542
in endothelial cells [6] or with SB-505124 in synovial fi-
broblasts [34] attenuates TGFβ1-induced phosphoryl-
ation of Smad1/5. Furthermore, by knocking down
ALK5, it has been shown by others that this receptor is
necessary for TGFβ-induced Smad1/5 phosphorylation
[3, 6]. Possibly, ALK5 can directly phosphorylate Smad1/
5 independently of BMP type I receptors in cartilage.
Direct phosphorylation of Smad1 by caALK5 has been
demonstrated by in vitro kinase assays [35, 38], and it
has been shown that TGFβ1-induced Smad1 phosphor-
ylation is inhibited in cells expressing a kinase defective
ALK5 variant: ALK5KR [38]. Together, these studies in-
dicate a direct induction of pSmad1/5 by ALK5, which
would be blocked by SB-505124, but challenge the
dogma that ALK5 cannot directly interact with Smad1
[36, 37]. In contrast, multiple studies show that in the
absence of BMP type I receptors, TGFβ1-induced
pSmad1/5 is reduced [3, 6] indicating at least a role for
these receptors.
Apart from R-Smad phosphorylation, TGFβ1 also in-
duces TAK1 activation, a key component of Smad-
independent TGFβ signaling [5]. Noteworthy, with the
use of the specific TAK1 kinase inhibitor (5Z)-7-Oxo-
zeaenol [17] at 0.5 μM, we showed that TAK1 kinase ac-
tivity facilitates canonical C-terminal R-Smad
phosphorylation in chondrocytes and cartilage. Previous
studies support a role for TAK1 in R-Smad-dependent
signaling; with the use of cartilage-specific TAK1 knock-
out animals, it has been shown that loss of TAK1 greatly
diminishes BMP-induced C-terminal Smad1/5 phos-
phorylation while not affecting total R-Smad levels [39,
40]. Furthermore, tissue specific knockout of TAK1 in
mesenchymal cells of neural crest origin shows that also
C-terminal Smad2/3 phosphorylation is inhibited in the
absence of TAK1 [41]. The pronounced effects of TAK1
on canonical C-terminal Smad phosphorylation have
been ascribed to TAK1-induced Smad-linker phosphor-
ylation, a post-translational Smad modification [41, 42].
Linker modification of R-Smads is an essential aspect
of TGFβ1-signaling (reviewed in [43, 44]). The linker re-
gion of R-Smads contains threonine and serine residues
that can be phosphorylated by various intracellular ki-
nases like extracellular signal-regulated kinases (ERK),
cyclin-depdendent kinases (CDKs) and JNKs [43, 45].
Degradation, nuclear transport and interaction of R-
Smads with other proteins are regulated by phosphoryl-
ation of this region, enabling context-dependent TGFβ
signaling [43, 44]. TAK1 can directly interact with R-
Smads via the R-Smad MH2 domain [42], and phosphor-
ylate, e.g. Smad2 at threonine 220 (Thr-220). Phosphor-
ylation of this threonine greatly affects cellular
localization and transcriptional activity of this Smad [41,
42]. TAK1 kinase activity is essential for this interaction
of TAK1 with R-Smads [42]. As a consequence of this
kinase dependency, it has been reported that the use of
(5Z)-7-Oxozeaenol results in similar effects on C-
terminal Smad1/5 and Smad2/3 phosphorylation as
knockout of TAK1 [41]. We did not have access to
cartilage-specific TAK1 knockout animals, but with the
use of (5Z)-7-Oxozeaenol, we show for the first time
(See figure on previous page.)
Fig. 3 SB-505124 fully and (5Z)-7-Oxozeaenol partly inhibits transforming growth factor β1 (TGFβ1)-induced Smad-dependent gene expression
whereas LDN-193189 does not. a Primary bovine chondrocytes were pre-incubated with 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol or 0.05 μM
LDN-193189 for 1 h, and subsequently stimulated with 1 ng/ml TGFβ1 for 2 h and 24 h. With the use of quantitative (q)PCR, expression of
bSerpine1 was measured as response gene for pSmad3 signaling after 2 h, and bId1 for pSmad1/5 signaling after 2 h. b The pSmad3 responsive
CAGA12-luciferase (CAGA12-luc) construct was placed in primary chondrocytes with the use of an adenovirus, and cells were stimulated with 1 ng/ml TGFβ1
for 8 h with or without inhibitors after 2 days. c Primary chondrocytes were stimulated with 1 ng/ml TGFβ1 for 24 h and gene expression was measured
using validated cDNA-specific primers and qPCR. MMP matrix metalloproteinase, NGF nerve growth factor, ALK5 activin receptor-like kinase 5. d Gene ex-
pression was measured after pre-incubation of chondrocytes for 1 h with inhibitors followed by stimulation with 1 ng/ml TGFβ1 for 24 h. For qPCR data,
average ± sd (mean ± sd) was plotted, with each dot representing the average of one donor (a) or four donors (c and d). Analysis was performed using
one-way analysis of variance with Tukey’s post-hoc test: *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001. A change of 1 ΔΔCt equals twofold upregulation
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Fig. 4 In cartilage, SB-505124 fully inhibits and (5Z)-7-Oxozeaenol partly inhibits transforming growth factor β1 (TGFβ1)-induced Smad2/3 phosphorylation
and gene expression, whereas LDN-193189 does not. a Bovine cartilage explants were pre-incubated ex vivo with 5 μM SB-505124, 0.5 μM (5Z)-7-Oxozeaenol
or 0.05 μM LDN-193189 for 1 h, and subsequently stimulated with 1 ng/ml TGFβ1 for 2 h, after which phosphorylated Smads were visualized by western blot
using specific antibodies. kDa kilodalton. bWith the use of quantitative (q)PCR, expression of bSerpine1 was measured as response gene for pSmad3 signaling
after 24 h, and bId1 for pSmad1/5 signaling after 24 h. c Gene expression was measured after pre-incubation of explants for 1 h with inhibitors followed by
stimulation with 1 ng/ml TGFβ1 for 24 h. For qPCR data, average ± sd (mean± sd) was plotted, with each dot representing the average of one donor (b) or
four donors (c). Analysis was performed using one-way analysis of variance with Tukey’s post-hoc test: *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001). A change of 1 ΔΔCt
equals twofold upregulation or downregulation. TGF transforming growth factor, COL2A1 = collagen type II alpha 1 chain MMP matrix metalloproteinase,
NGF nerve growth factor, ALK5 activin receptor-like kinase, JUNB = JunB proto-oncogene, FN1 = fibronectin 1
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that this selective TAK1 kinase inhibitor greatly affects
TGFβ1-induced C-terminal R-Smad phosphorylation
both in vitro and ex vivo in articular cartilage.
A limitation of our study is the possibly imperfect spe-
cificity of the used compounds, making it possible that
off-target effects can explain our observations and inter-
fere with our conclusions. However, in the experiments
with the caALKs, we did not observe a significant effect
of SB-505124 or (5Z)-7-Oxozeaenol on caALK1-induced
pSmad1/5, or an effect of (5Z)-7-Oxozeaenol on
caALK5-induced pSmad2. Therefore we do not think
that these compounds have off-target effects on ALK1.
Furthermore, a dose-response curve showed that SB-
505124 inhibited TGFβ-induced Smad1/5 phosphoryl-
ation more potently than Smad2/3 phosphorylation,
demonstrating that this effect of SB-505124 on TGFβ
signaling is not an off-target effect obtained at high dos-
age, and this compound therefore cannot be used to spe-
cifically inhibit TGFβ-induced Smad2 in chondrocytes.
Another limitation of our study is that we did not in-
clude in vivo data. Unfortunately, the in vivo use of both
SB-505124 and LDN-193189 is difficult because of their
unfavorable pharmacokinetic properties, resulting in the
need for daily re-administation via injection [33]. Up to
now, only one study has used SB-505124 as a TGFβ
blocker in vivo in a model of OA; i.e. in anterior cruciate
ligament transection in mice [46]. In this study, inhib-
ition of TGFβ signaling with 1 mg/kg/day of SB-505124
attenuated OA development, confirming that inhibition
of TGFβ signaling with a small molecule inhibitor is a
feasible and promising approach to treat OA. However,
the use of a higher dose of SB-505124 (2.5 mg/kg/day)
was detrimental for cartilage because this resulted in
proteoglycan depletion, indicating that total TGFβ inhib-
ition comes with a risk. Possibly, a small molecule in-
hibitor that prevents TGFβ-induced pSmad1/5 but
leaves pSmad2 unaffected will not have this risk. To our
knowledge, both LDN-193189 and (5Z)-7-Oxozeaenol
have not been used in vivo to study their effects on OA
development. They have been used in other applications,
e.g. LDN-193189 in atherosclerosis research and (5Z)-7-
Oxozeaenol in cancer studies; however, this was not to
specifically modulate TGFβ signaling but to inhibit BMP
and TAK1 signaling, respectively. Therefore it is as yet
unknown how these inhibitors modulate TGFβ signaling
in vivo or in OA.
Conclusions
In conclusion, with the use of the small molecule inhibi-
tors SB-505124 and LDN-193189 we were unable to dir-
ect TGFβ1-signaling towards either Smad1/5 or Smad2/
3 phosphorylation in cartilage. Our data suggest that in
cartilage, ALK5 plays a central role in both TGFβ-
induced Smad1/5 and Smad2/3 phosphorylation, making
it difficult to separate the Smad pathways with the use of
currently available intracellular small molecule inhibitors
of the ALK receptors. Furthermore, we showed that
treatment with the TAK1 inhibitor (5Z)-7-Oxozeaenol
Fig. 5 Schematic overview of transforming growth factor β (TGFβ)-induced Smad signaling versus bone morphogenic protein (BMP)-induced
Smad signaling in cartilage and the effects of small molecule inhibitors. To signal, a TGFβ dimer binds and induces dimerization of its type II
receptor: TGFBR2. This complex subsequently recruits a dimer of the type I receptors TGFβ can bind: activin receptor-like kinase (ALK)1, ALK2, ALK3
and ALK5. Signaling complexes containing ALK5 homodimers will induce Smad2/3 phosphorylation, whereas complexes containing ALK5 combined
with ALK1, ALK2 or ALK3 will induce both Smad1/5 and Smad2/3 phosphorylation. However, our current study shows that the kinase domain of ALK1,
ALK2 or ALK3 is not involved in TGFβ-induced pSmad1/5 because TGFβ-induced pSmad1/5 is inhibited by SB-505124 but not by LDN-193189. Possibly,
ALK1, ALK2 and ALK3 function to recruit Smad1/5 to TGFβ receptor complexes but are not activated by TGFBR2 themselves and are therefore not
active. For BMP signaling a heterotetrameric complex is also formed from its different type II and type I receptors; BMPR2, ACVR2a and ACVR2b can be
used as type II receptors, whereas ALK1, ALK2, ALK3 and ALK6 function as type I receptors. These complexes will induce pSmad1/5 but this is potently
blocked by LDN-193189 (as shown in this article) or partially blocked by (5Z)-7-Oxozeaenol (evidence from the literature)
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inhibits TGFβ-induced C-terminal phosphorylation of
both Smad1/5 and Smad2/3, suggesting a link between
the non-canonical and the canonical TGFβ pathway in
cartilage.
Additional files
Additional file 1: Figure S1. Expression of ALK1, ALK2, ALK3 and ALK5
mRNA in primary bovine cartilage and chondrocytes. a With the use of
qPCR, expression of ALK1, ALK2, ALK3 and ALK5 was measured in both
freshly isolated cartilage explants and in primary chondrocytes after
1 week of cell culture in DMEM/F12 supplemented with 10% non-heat-
inactivated FCS without passage. All four ALKs were readily detected in
both groups, but expression of all the receptors was higher in freshly
isolated tissue. For calculations of the -ΔCt, two reference genes were
used: bGapdh and bRps14. (PDF 2065 kb)
Additional file 2: Figure S3. Quantification of TGFβ-induced pSmad2
and pSmad1/5 in cartilage explants. Quantification of the western blot as
shown in Fig. 4a. The experiment was repeated three times. Significance
was not obtained due to variation between experiments. pSmad levels
were normalized to vinculin levels and plotted as a relative amount in
arbitrary units (AU) compared to the control group. (PDF 2278 kb)
Additional file 3: Figure S2. LDN-193189 in a concentration of 0.05 μM
inhibits basal ID1 expression in cartilage explants. Primary chondrocytes
were incubated with LDN-193189 for 2 h in a dose of 0.05 μM and bId1
expression was measured using qPCR. LDN-193189 significantly inhibited
bId1 expression showing the bioactivity of this compound in cartilage
explants. (PDF 2122 kb)
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regulated Smad; TAK1: TGFβ-activated kinase 1, also known as: mitogen-
activated protein kinase kinase kinase 7 (MAP3K7); TGFβ: Transforming




This study was supported by a grant from: The Netherlands Organization for
Scientific Research (NWO, ZonMW) for AvC, AGV, MJG and PtD, and the
Dutch Arthritis Association (Reumafonds) for WM, EBD and PvdK.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article (and its supplementary information files).
Authors' contributions
Conception and design: AC, EBD and PK. Collection and assembly of data:
AC and WM. Analysis and interpretation of data: AC, WM, AGV, MJG, PD, EBD
and PK. Drafting of the manuscript: AC, EBD and PK. Critical revision: AC, WM,
AGV, MJG, PD, EBD and PK. Final approval of the article: AC, WM, AGV, MJG,








Not applicable. No live animals were used for this study, nor were animals
specifically killed for this study to obtain material; all animals were
slaughtered for their meat. Therefore ethical approval of an ethics committee
was not required, nor was it applicable for this study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Experimental Rheumatology, Radboud University Medical Center, Nijmegen,
The Netherlands. 2Orthopaedics Research Lab, Radboud University Medical
Center, Nijmegen, The Netherlands. 3Department of Molecular Cell Biology
and Cancer Genomics Centre Netherlands, Leiden University Medical Center,
Leiden, The Netherlands.
Received: 18 November 2016 Accepted: 2 May 2017
References
1. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane
to nucleus through SMAD proteins. Nature. 1997;390(6659):465–71.
2. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell
Biol. 2008;40(3):383–408.
3. Daly AC, Randall RA, Hill CS. Transforming growth factor beta-induced
Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor
complexes and is essential for anchorage-independent growth. Mol Cell
Biol. 2008;28(22):6889–902.
4. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P.
Balancing the activation state of the endothelium via two distinct TGF-beta
type I receptors. EMBO J. 2002;21(7):1743–53.
5. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways
in TGF-beta family signalling. Nature. 2003;425(6958):577–84.
6. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C,
Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic
mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003;12(4):817–28.
7. Finnson KW, Parker WL, ten Dijke P, Thorikay M, Philip A. ALK1 opposes
ALK5/Smad3 signaling and expression of extracellular matrix components in
human chondrocytes. J Bone Miner Res. 2008;23(6):896–906.
8. Ferguson CM, Schwarz EM, Reynolds PR, Puzas JE, Rosier RN, O'Keefe RJ.
Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition
of chondrocyte maturation. Endocrinology. 2000;141(12):4728–35.
9. Yang X, Chen L, Xu X, Li C, Huang C, Deng CX. TGF-beta/Smad3 signals
repress chondrocyte hypertrophic differentiation and are required for
maintaining articular cartilage. J Cell Biol. 2001;153(1):35–46.
10. Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F.
Functions of transforming growth factor-beta family type I receptors and
Smad proteins in the hypertrophic maturation and osteoblastic
differentiation of chondrocytes. J Biol Chem. 2002;277(37):33545–58.
11. Retting KN, Song B, Yoon BS, Lyons KM. BMP canonical Smad signaling
through Smad1 and Smad5 is required for endochondral bone formation.
Development. 2009;136(7):1093–104.
12. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS,
Adams SL. Smad-Runx interactions during chondrocyte maturation. J Bone
Joint Surg Am. 2001;83-A(Suppl 1(Pt 1)):S15–22.
13. Blaney Davidson EN, Remst DF, Vitters EL, van Beuningen HM, Blom AB,
Goumans MJ, van den Berg WB, van der Kraan PM. Increase in ALK1/ALK5
ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans
and mice. J Immunol. 2009;182(12):7937–45.
14. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C,
Bloch KD, Peterson RT. Structure-activity relationship study of bone
van Caam et al. Arthritis Research & Therapy  (2017) 19:112 Page 12 of 13
morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett.
2008;18(15):4388–92.
15. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124 is a selective
inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5,
and ALK7. Mol Pharmacol. 2004;65(3):744–52.
16. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors
of the TGFss and BMP pathways. Cell Signal. 2011;23(11):1831–42.
17. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M,
Mihara M, Tsuchiya M, Matsumoto K. A resorcylic acid lactone, 5Z-7-
oxozeaenol, prevents inflammation by inhibiting the catalytic activity of
TAK1 MAPK kinase kinase. J Biol Chem. 2003;278(20):18485–90.
18. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, Gu RF, Roth M, Toader D,
Saeh JC, et al. Mechanism and in vitro pharmacology of TAK1 inhibition by
(5Z)-7-Oxozeaenol. ACS Chem Biol. 2013;8(3):643–50.
19. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase
(MMP-1, MMP-13) genes in arthritis: integration of complex signaling
pathways for the recruitment of gene-specific transcription factors. Arthritis
Res. 2002;4(3):157–64.
20. Cheng J, Hu X, Dai L, Zhang X, Ren B, Shi W, Liu Z, Duan X, Zhang J, Fu X,
et al. Inhibition of transforming growth factor beta-activated kinase 1
prevents inflammation-related cartilage degradation in osteoarthritis. Sci
Rep. 2016;6:34497.
21. van Caam A, Blaney Davidson E, Garcia de Vinuesa A, van Geffen E, van den
Berg W, Goumans MJ, ten Dijke P, van der Kraan P. The high affinity ALK1-
ligand BMP9 induces a hypertrophy-like state in chondrocytes that is
antagonized by TGFβ1. Osteoarthritis Cartilage. 2015;23(6):985–95.
22. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding
of Smad3 and Smad4 to critical TGF beta-inducible elements in the
promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J.
1998;17(11):3091–100.
23. Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang
Y, Triffitt JT, Cuny GD, Yu PB, et al. A new class of small molecule inhibitor
of BMP signaling. PLoS One. 2013;8(4), e62721.
24. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo
H, Heldin CH, Miyazono K. Identification of type I receptors for osteogenic
protein-1 and bone morphogenetic protein-4. J Biol Chem. 1994;269(25):
16985–8.
25. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9
and BMP10 as functional activators of the orphan activin receptor-like
kinase 1 (ALK1) in endothelial cells. Blood. 2007;109(5):1953–61.
26. Luo J, Tang M, Huang J, He BC, Gao JL, Chen L, Zuo GW, Zhang W, Luo Q,
Shi Q, et al. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for
BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol
Chem. 2010;285(38):29588–98.
27. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM,
Thorikay M, ten Dijke P, Mertens PR, Breitkopf K, et al. Id1 is a critical
mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate
cells. Hepatology. 2006;43(5):1032–41.
28. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng
C, Kucherlapati R, Bottinger EP, Roberts AB. Functional characterization of
transforming growth factor beta signaling in Smad2- and Smad3-deficient
fibroblasts. J Biol Chem. 2001;276(23):19945–53.
29. Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R. Efficient TGF-beta
induction of the Smad7 gene requires cooperation between AP-1, Sp1, and
Smad proteins on the mouse Smad7 promoter. J Biol Chem. 2000;275(37):
29023–30.
30. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and
functional characterization of a Smad binding element (SBE) in the JunB
promoter that acts as a transforming growth factor-beta, activin, and bone
morphogenetic protein-inducible enhancer. J Biol Chem. 1998;273(33):
21145–52.
31. Hatakeyama Y, Nguyen J, Wang X, Nuckolls GH, Shum L. Smad signaling in
mesenchymal and chondroprogenitor cells. J Bone Joint Surg Am. 2003;85-
A Suppl 3:13–8.
32. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to
stress signaling: Smad engages stress response factor ATF3 for Id1
repression in epithelial cells. Mol Cell. 2003;11(4):915–26.
33. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW,
McManus PM, Katagiri T, Sachidanandan C, et al. BMP type I receptor
inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):
1363–9.
34. Remst DF, Blaney Davidson EN, Vitters EL, Bank RA, van den Berg WB, van
der Kraan PM. TGF-β induces Lysyl hydroxylase 2b in human synovial
osteoarthritic fibroblasts through ALK5 signaling. Cell Tissue Res. 2014;
355(1):163–71.
35. Wrighton KH, Lin X, Yu PB, Feng XH. Transforming growth factor {beta} can
stimulate smad1 phosphorylation independently of bone morphogenic
protein receptors. J Biol Chem. 2009;284(15):9755–63.
36. Persson U, Izumi H, Souchelnytskyi S, Itoh S, Grimsby S, Engstrom U, Heldin
CH, Funa K, ten Dijke P. The L45 loop in type I receptors for TGF-beta family
members is a critical determinant in specifying Smad isoform activation.
FEBS Lett. 1998;434(1-2):83–7.
37. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, Massague J.
Determinants of specificity in TGF-beta signal transduction. Genes Dev.
1998;12(14):2144–52.
38. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF. TGFbeta-
stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and
mediates the pro-migratory TGFbeta switch. EMBO J. 2009;28(2):88–98.
39. Gunnell LM, Jonason JH, Loiselle AE, Kohn A, Schwarz EM, Hilton MJ,
O'Keefe RJ. TAK1 regulates cartilage and joint development via the MAPK
and BMP signaling pathways. J Bone Miner Res. 2010;25(8):1784–97.
40. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, Gygi S,
Glimcher LH. TAK1 is an essential regulator of BMP signalling in cartilage.
EMBO J. 2009;28(14):2028–41.
41. Yumoto K, Thomas PS, Lane J, Matsuzaki K, Inagaki M, Ninomiya-Tsuji J,
Scott GJ, Ray MK, Ishii M, Maxson R, et al. TGF-beta-activated kinase 1 (Tak1)
mediates agonist-induced Smad activation and linker region
phosphorylation in embryonic craniofacial neural crest-derived cells. J Biol
Chem. 2013;288(19):13467–80.
42. Hoffmann A, Preobrazhenska O, Wodarczyk C, Medler Y, Winkel A, Shahab S,
Huylebroeck D, Gross G, Verschueren K. Transforming growth factor-beta-
activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and
interferes with osteogenesis in murine mesenchymal progenitors. J Biol
Chem. 2005;280(29):27271–83.
43. Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-beta
signaling. Cytokine Growth Factor Rev. 2013;24(4):385–99.
44. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;
13(10):616–30.
45. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN,
Manova-Todorova K, Macias MJ, et al. Nuclear CDKs drive Smad
transcriptional activation and turnover in BMP and TGF-beta pathways. Cell.
2009;139(4):757–69.
46. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB, Frassica FJ, Chang
W, Yao J, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of
subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704–12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
van Caam et al. Arthritis Research & Therapy  (2017) 19:112 Page 13 of 13
